Malignant genitourinary tumors have demonstrated a rising incidence and are characterized by significant morbidity and mortality. Advances in sequencing technologies have greatly enhanced our understanding of the genetic and molecular mechanisms that drive tumor biology. In recent years, spatial transcriptomics technologies have rapidly evolved, enabling precise quantification and visualization of gene expression within the spatial context of tissues. Unlike conventional transcriptomics, which focuses on gene expression levels, spatial transcriptomics provides additional insights into the spatial distribution of genes within tissues, cellular composition, and cell-to-cell interactions within biological samples. In this narrative review, we outline the emerging role and future potential of spatial transcriptomics technology in genitourinary cancers.
Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification of RCC is primarily based on distinct morphological and molecular characteristics, with two broad categories: clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC). Clear cell RCC is the predominant subtype, representing about 70–80% of all RCC cases, while non-clear cell subtypes collectively make up the remaining 20–30%. Non-clear cell RCC encompasses many histopathological variants, each with unique biological and clinical characteristics. Additionally, any RCC subtype can undergo sarcomatoid dedifferentiation, which is associated with poor prognosis and rapid disease progression. Recent advances in molecular profiling have also led to the identification of molecularly defined variants, further highlighting the complexity of this disease. While immunotherapy has shown efficacy in some RCC variants and subpopulations, significant gaps remain in the treatment of rare subtypes. This review explores the outcomes of immunotherapy across RCC subtypes, including rare variants, and highlights opportunities for improving care through novel therapies, biomarker-driven approaches, and inclusive clinical trial designs.
Background/Objectives: Penile squamous cell carcinoma (PSCC) is a rare malignancy with poor prognosis in advanced and recurrent disease, and therapeutic options remain limited. Increasing evidence suggests that the tumor immune microenvironment (TIME), including immune cell composition and spatial organization, plays a critical role in tumor progression and survival outcomes. This study aimed to characterize immune cell density and geospatial clustering patterns within the TIME of PSCC and to evaluate their associations with clinical outcomes. Methods: Multiplex immunofluorescence (mIF) was performed on tumor samples from 57 patients with PSCC using a panel of immune markers to identify lymphoid and myeloid cell populations. Immune cell densities were quantified within tumoral and stromal compartments. Spatial relationships among immune cells and between immune cells and tumor cells were analyzed using point pattern analysis. Survival outcomes, including overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS), were assessed using Kaplan–Meier methods and Cox proportional hazards models, with analyses stratified by nodal and human papillomavirus (HPV) status. Results: Higher intratumoral and stromal densities of pro-immunogenic M1 macrophages were associated with improved OS. Increased densities of CD3+CD4+ helper T cells in both compartments were also associated with favorable survival outcomes. In contrast, close clustering of pro-tumorigenic M2 macrophages with tumor cells and with one another was associated with worse OS, RFS, and CSS. Bivariate clustering of helper T cells with tumor cells was associated with improved OS, including among patients with node-positive disease. Survival outcomes did not differ significantly by HPV status in patients with high helper T cell clustering. Conclusions: Immune cell density and spatial organization within the TIME are associated with survival outcomes in PSCC. Favorable patterns involving helper T cells and M1 macrophages correlate with improved survival, whereas clustering of M2 macrophages is associated with poorer outcomes, supporting the relevance of spatial immune profiling in this disease.
PURPOSE: Ifosfamide is traditionally administered in an inpatient setting because of risks of neurotoxicity and hemorrhagic cystitis. To optimize quality of life while tackling the rising cancer care costs, organizations have been shifting chemotherapy administration to outpatient settings. This single-center, retrospective cohort study evaluated the safety and feasibility of administering ifosfamide-based chemotherapy regimens, MAI (mesna, doxorubicin, ifosfamide) and IE (ifosfamide, etoposide), in an outpatient service at a National Cancer Institute–designated Comprehensive Cancer Center. METHODS: This single-center study included patients age 18-60 years treated between 2018 and 2024. Fifty-eight patients receiving MAI or IE were managed either through the outpatient service or in the inpatient setting. Clinical outcomes, including readmissions, urgent care visits, toxicities, and treatment completion, were compared. Hospital resource utilization was assessed by estimating average inpatient bed days saved. RESULTS: The outpatient service saved an estimated 16.2 bed days per patient and 3.7 bed days per cycle. Clinical outcomes were comparable, with similar readmission (18.1% v 19.2%) and urgent care visit rates (5.5% v 4.8%), and no cases of hemorrhagic cystitis were reported. Grade ≥3 hematologic toxicities and treatment completion rates (>90%) were also similar across both arms. CONCLUSION: These findings demonstrate that ifosfamide-based regimens through a structured outpatient model are both safe and reducing hospital resource utilization while maintaining treatment adherence and patient safety.
Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited therapeutic options in advanced and recurrent diseases. Advanced PSCC is typically managed with multimodal therapy, including neoadjuvant chemotherapy or chemoradiation followed by surgery; however, durable responses remain uncommon, and outcomes after recurrence are poor. Cancer vaccines represent a promising immunotherapeutic strategy, as these treatments induce tumor-specific immunity and heightened immune surveillance against penile cancer cells. While therapeutic cancer vaccines have not yet demonstrated consistent clinical efficacy as monotherapy in PSCC, their integration with complementary immune-modulating approaches, particularly immune checkpoint blockade, represents a rational strategy to enhance antitumor immunity. This review summarizes the rationale for vaccine development in PSCC, with emphasis on HPV-derived antigens, neoantigens, and emerging tumor-associated targets. We examine major vaccine platforms, including viral-vector, peptide-based, nucleic acid, and dendritic cell-based approaches. We also discuss how spatial transcriptomics, single-cell RNA sequencing, artificial intelligence-assisted antigen prediction, and nanotechnology-enhanced delivery systems may support future personalized vaccine development. Overall, therapeutic vaccines remain investigational in PSCC but may become relevant within biomarker-driven, combination-based immunotherapy strategies.